fluzoparib + chidamide

Fluzoparib + chidamide is an investigational combination therapy consisting of two small molecule drugs with distinct mechanisms of action, being studied primarily for the treatment of advanced breast cancer, particularly HER2-negative and triple-negative subtypes. Fluzoparib is a poly (ADP-ribose) polymerase (PARP) inhibitor that impairs DNA repair in tumor cells with homologous recombination deficiency, leading to cell death. Chidamide is a selective histone deacetylase (HDAC) inhibitor that modulates gene expression through epigenetic mechanisms and can enhance immune response and reverse drug resistance. Preclinical studies indicate that this combination may overcome resistance to PARP inhibitors by downregulating DNA repair proteins such as RAD51 and MRE11, inducing cell cycle arrest at G2/M phase, and promoting apoptosis in resistant cancer cells. The combination has shown promising antitumor activity in vitro and in vivo models[7]. Clinical trials are ongoing for HRD-positive HER2-negative advanced breast cancer[1][3][5].